Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438226 | 0.93 | CYP2C8 (0.81) | CYP2C8CYP3A4KCNH2NR1I2ABL1 | |
| SCHEMBL1936786 | 0.93 | CYP2C8 (0.69) | CYP2C8CYP3A4KCNH2NR1I2ABL1 | |
| SCHEMBL2996484 | 0.91 | CYP2C8 (0.58) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2985231 | 0.85 | CYP2C8 (0.69) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL1936169 | 0.85 | CYP2C8 (0.80) | CYP2C8CYP3A4KCNH2NR1I2ABL1 | |
| SCHEMBL1936612 | 0.85 | CYP2C8 (0.58) | CYP2C8CYP3A4KCNH2NR1I2ABL1 | |
| SCHEMBL2141972 | 0.83 | CYP2C8 (1.00) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2993440 | 0.79 | CYP2C8 (0.82) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL1936904 | 0.78 | CYP2C8 (0.56) | CYP2C8CYP3A4KCNH2NR1I2ABL1 | |
| SCHEMBL1935138 | 0.78 | ALDH1A1 (0.47) | CYP2C8CYP3A4KCNH2NR1I2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536338-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-8198449-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 168/4885CYP3A4 230/4885KCNH2 3450/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 168/4885CYP3A4 230/4885KCNH2 3450/4885 |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 168/4885CYP3A4 230/4885KCNH2 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.